Specific Ovarian Cancer-tailored Immunotherapy Appears Effective in Mouse Models

Specific Ovarian Cancer-tailored Immunotherapy Appears Effective in Mouse Models
Directing cancer immunotherapy against a specific protein on the surface of ovarian cancer cells may prove to be a tumor-specific approach to killing malignant cells while leaving healthy cells intact. In the study “Follicle stimulating hormone receptor is expressed by most ovarian cancer subtypes and is a safe and effective immunotherapeutic target,” published in the scientific journal Clinical Cancer ResearchWistar Institute researchers analyzed human ovarian samples from 77 people with ovarian cancer and 20 healthy volunteers, discovering that a protein named follicle stimulating hormone receptor (FSHR) is expressed on the surface of different types of ovarian tumors but not on healthy tissues of non-ovarian origin. Specifically, FSHR was found in 33 percent of clear cell ovarian carcinoma, 67 percent of mucinous ovarian carcinomas, and 70 percent of endometrioid carcinomas. "Finding a receptor expressed exclusively on ovarian cells allows us to utilize groundbreaking targeted T-cell technology to potentially eliminate cancerous cells in patients," senior study author Dr. José R. Conejo-Garcia said in a press release. This means that treatments targeting this receptor would only affect ovarian tissue and eliminate the cancerous cells without affecting other tissues. Usually, immunotherapies that direct T-cells to eliminate specific
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *